Roundup: What You Missed at CRS 2018

Here’s what you may have missed from this weekend’s Cardiometabolic Risk Summit.

Cardiometabolic Risk Summit Educates More Than 650 Clinicians in San Antonio

The Cardiometabolic Risk Summit, an official meeting of Consultant360, took place September 14-16 at the Marriott San Antonio Rivercenter.

Resistant Hypertension: Current and Future Management Strategies

In light of the current hypertension epidemic, Florian Rader, MD, advised about distinguishing resistant hypertension from mimics and described the latest treatment options, as well as those on the horizon.

Hypertension Management: Translating the New Guidelines Into Practice

The 2017 AHA/ACC hypertension guidelines will likely change how most physicians measure and manage BP, said F. Wilford Germino, MD, at CRS 2018.

PCSK9 Inhibitors: Cardiovascular Outcomes and Challenges to Patients’ Access

James A. Underberg, MD, outlined recent cardiovascular outcomes evidence for PCSK9 inhibitors and discussed strategies for improving access to therapy for appropriate patients.

Newer GLP-1 RAs and Their Role in Type 2 Diabetes Management

Javier Morales, MD, offered a review of glucagon-like peptide-1 receptor agonists and how they fit into the management of patients with type 2 diabetes.